![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1755294
¼¼°èÀÇ ½Å°æÇ÷°ü ³» ÄÚÀÏ ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2025-2034³â)Neuroendovascular Coil Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
¼¼°èÀÇ ½Å°æÇ÷°ü ³» ÄÚÀÏ ½ÃÀåÀº 2024³â 10¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç 2034³â¿¡´Â 19¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, CAGR 6%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. °íÇ÷¾Ð, ´ç´¢º´, Èí¿¬°ú °°Àº À§Çè ¿äÀΰú ÇÔ²² ³úµ¿¸Æ·ù ¹× ÇãÇ÷¼º ³úÁ¹ÁßÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÏ¸é¼ ½Å°æÇ÷°ü ³» ÄÚÀÏ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °í·ÉÈ Àα¸ Áõ°¡µµ ³úµ¿¸Æ·ù Áø´Ü »ç·Ê Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÄÚÀÏ Àç·á, µðÀÚÀÎ, Àü´Þ ½Ã½ºÅÛ ºÐ¾ßÀÇ Çõ½ÅÀº ³»Ç÷°ü Ä¡·áÀÇ ¾ÈÀü¼º, Á¤È®¼º, È¿°ú¼ºÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. ÃÖ±Ù ±â¼ú ¹ßÀüÀ¸·Î FDA ½ÂÀÎÀ» ¹ÞÀº »õ·Î¿î ÄÚÀϸµ ½Ã½ºÅÛÀÌ ¿©·¯ °³ Ãâ½ÃµÇ¾úÀ¸¸ç, ÀÌ´Â ÀÌ Ä¡·á¹ýÀÇ ºü¸¥ ¹ßÀüÀ» ¹Ý¿µÇÕ´Ï´Ù.
ÀÌ »õ·Î¿î ÄÚÀÏÀº ´õ À¯¿¬ÇÏ°í ºÐ¸® °¡´ÉÇÏ¸ç ¹æ»ç¼± Åõ°ú¼ºÀÌ ³ô¾Æ º¹ÀâÇÑ Ç÷°ü ÇØºÎÇп¡¼µµ µ¿¸Æ·ù¸¦ Ä¡·áÇÏ´Â µ¥ ÀûÇÕÇÕ´Ï´Ù. ½Å°æÇ÷°ü ³» ÄÚÀϸµÀº ÀüÅëÀûÀÎ ¼ö¼úÀû Á¢±Ù ¹æ½Äº¸´Ù ÀýÂ÷Àû ÇÕº´Áõ À§ÇèÀÌ ³·¾Æ ÀÇ·áÁø »çÀÌ¿¡¼ äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÃÖ¼Ò Ä§½ÀÀû Ä¡·á´Â ºü¸¥ ȸº¹ ½Ã°£, ³·Àº À§Çè, ªÀº ÀÔ¿ø ±â°£À¸·Î ÀÎÇØ ÀÇ»çµé°ú ȯÀÚ ¸ðµÎ¿¡°Ô ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÉÀå Çùȸ(American Heart Association)¿Í ¹Ì±¹ ³úÁ¹Áß Çùȸ(American Stroke Association)´Â ´ëºÎºÐÀÇ ³ú³» µ¿¸Æ·ù À¯ÇüÀÇ Ãʱâ Ä¡·á·Î ½Å°æÇ÷°ü ³» ÄÚÀϸµÀ» ±ÇÀåÇϸç, ÀÌ´Â ¼ö¼úÀû Ŭ¸®ÇÎÀÇ Áß¿äÇÑ ´ë¾ÈÀ¸·Î ÀÚ¸®¸Å±èÇß½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 10¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 19¾ï ´Þ·¯ |
CAGR | 6% |
½Å°æÇ÷°ü ³» ÄÚÀÏ ½ÃÀå¿¡¼ º£¾î Ç÷¡Æ¼³Ñ ÄÚÀÏ ºÎ¹®Àº 2024³â¿¡ 52.8%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ÄÚÀÏÀº µÎ°³ ³» µ¿¸Æ·ù Ä¡·á¿¡ ´ëÇÑ ÀÓ»óÀû È¿°ú°¡ ÀÔÁõµÇ¾î ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. º£¾î Ç÷¡Æ¼³Ñ ÄÚÀÏÀº ÀÏ´Ü »ðÀÔµÇ¸é ½Ã°£ÀÌ Áö³ªµµ ½Å·ÚÇÒ ¼ö ÀÖ´Â µ¿¸Æ·ù Æó»ö È¿°ú¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ÄÚÀÏÀÇ ¿À·£ ÀÓ»ó ½ÇÀûÀ» ÅëÇØ ÇÕº´Áõ ¹ß»ý·üÀÌ ÃÖ¼ÒÈµÇ¾î ¸¹Àº °æ¿ì¿¡ ¼±È£µÇ´Â Á¦Ç°ÀÔ´Ï´Ù. ÀÔÁõµÈ ½Å·Ú¼ºÀº ¼±Áø±¹°ú ½ÅÈï ½ÃÀå ¸ðµÎ¿¡¼ ¼ö¿ä¸¦ °è¼Ó ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ º£¾î Ç÷¡Æ¼³Ñ ÄÚÀÏÀÇ °¡°Ý´ë´Â ºñ¿ë ¹Î°¨µµ°¡ Áß¿äÇÑ ¿äÀÎÀÌ µÇ°í »óȯÀÌ Ç×»ó °¡´ÉÇÑ °ÍÀº ¾Æ´Ñ ÀÇ·á ½Ã½ºÅÛ¿¡¼ ÀåÁ¡ÀÔ´Ï´Ù.
º´¿øÀº ½Å°æÇ÷°ü ³» ÄÚÀÏ ½ÃÀå¿¡¼ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇϸç 2024³â¿¡´Â 69.1%ÀÇ Á¡À¯À²À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°è º´¿øÀº µ¿¸Æ·ù ÄÚÀϸµ°ú °°Àº ½Ã°£ ¹Î°¨ÀûÀÎ ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ³úÁ¹Áß ¹× ½Å°æÇ÷°ü Ä¡·á Àü¿ë ºÎ¼¸¦ Á¡Á¡ ´õ ¸¹ÀÌ ¼³Ä¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àü¹® ºÎ¼´Â ³úÇ÷°ü Áúȯ Ä¡·á¿¡ ÇʼöÀûÀÎ ½Å°æÇ÷°ü ³» ÄÚÀÏÀÇ ¾ÈÁ¤Àû °ø±Þ¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ½Å°æÇÐÀû Ä¡·á¿Í ³úÁ¹Áß ÈÄ ÇÕº´Áõ ¿¹¹æ¿¡ ÃÊÁ¡À» ¸ÂÃß¸é¼ °í±Þ ÄÚÀÏ ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. °í¼Òµæ ±¹°¡¿¡¼´Â ¹Î°£ º¸Çè»ç ¹× °ø°ø ÀÇ·á ½Ã½ºÅÛÀÌ º´¿ø ±â¹Ý ³»Ç÷°ü Ä¡·á¿¡ ´ëÇÑ Áö¿ø º¸»ó Á¤Ã¥À» Á¦°øÇÕ´Ï´Ù.
¹Ì±¹ÀÇ ½Å°æÇ÷°ü ³» ÄÚÀÏ ¹Ì±¹ ½ÃÀåÀº 2034³â±îÁö 7¾ï 5,220¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡´Â Àü¹® ³úÁ¹Áß ¼¾ÅÍ¿Í ½Å°æ¿Ü°ú ºÎ¼°¡ ±¤¹üÀ§ÇÑ ³×Æ®¿öÅ©¸¦ Çü¼ºÇϰí ÀÖ¾î ¸¹Àº ½Å°æÇ÷°ü ½Ã¼úÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °ß°íÇÑ ÀÇ·á ÀÎÇÁ¶ó¸¦ ÅëÇØ ½Å°æÇ÷°ü ³» ÄÚÀÏÀÇ »ç¿ëÀÌ ³Î¸® º¸±ÞµÇ°í ÀÖÀ¸¸ç, »õ·Î¿î ±â¼úÀÇ µµÀÔµµ Áö¼ÓÀûÀ¸·Î ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÇ·á ½Ã¼³ÀÇ ²ÙÁØÇÑ ¼ºÀå°ú ½Å°æÇ÷°ü Ä¡·á ±â¼úÀÇ º¸±Þ È®´ë´Â ¹Ì±¹ ½ÃÀåÀÇ È®Àå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
¼¼°èÀÇ ½Å°æÇ÷°ü ³» ÄÚÀÏ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Acandis, Allium Medical, Balt, Boston Scientific, Cardinal Health, Cook Medical, Kaneka, Medtronic, MicroPort, MicroVention, Penumbra, Rapid Medical, Shape Memory Medical, Stryker, Terumo µîÀÔ´Ï´Ù. ½Å°æÇ÷°ü ³» ÄÚÀÏ ½ÃÀå¿¡¼ ÀÔÁö¸¦ ´ÙÁö±â À§ÇØ ±â¾÷µéÀº ´Ù¾çÇÑ Àü·«À» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡´Â °í±Þ ÄÚÀÏ ±â¼ú µµÀÔÀ» À§ÇÑ ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ´ë±Ô¸ð ÅõÀÚ, ƯÈ÷ ¾ÈÀü¼º, Á¤¹Ðµµ, Àü´Þ ¸ÞÄ¿´ÏÁò °³¼±¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. »õ·Î¿î ÄÚÀÏ Àç·á¿Í µðÀÚÀÎÀ» °³¹ßÇÔÀ¸·Î½á Á¦Á¶¾÷üµéÀº º¹ÀâÇÑ µ¿¸Æ·ù Ä¡·á¸¦ À§ÇÑ ´õ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ¶ÇÇÑ º´¿ø ¹× ÀÇ·á ¼¾ÅÍ¿ÍÀÇ ÆÄÆ®³Ê½Ê°ú Çù·ÂÀ» ÅëÇØ Áö¸®Àû ¹üÀ§¸¦ È®ÀåÇϰí ÀÖÀ¸¸ç, ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ ºü¸£°Ô ¹ßÀüÇÏ´Â Áö¿ª¿¡¼ À̸¦ °ÈÇϰí ÀÖ½À´Ï´Ù.
The Global Neuroendovascular Coil Market was valued at USD 1 billion in 2024 and is estimated to grow at a CAGR of 6% to reach USD 1.9 billion by 2034. The increasing prevalence of brain aneurysms and ischemic strokes, coupled with risk factors like hypertension, diabetes, and smoking, is fueling the demand for neuroendovascular coils. The aging population is also contributing to the rise in cerebral aneurysm diagnoses. Innovations in coil materials, designs, and delivery systems have made endovascular therapy safer, more accurate, and more effective. Recent advancements in technology have led to FDA approvals for several new coiling systems, which reflect the rapid development of this treatment method.
These new coils are more conformable, detachable, and radiopaque, making them suitable for treating aneurysms, even in complex vascular anatomies. Endovascular coiling has been shown to have a lower risk of procedural complications than traditional surgical approaches, contributing to its growing adoption by physicians. Minimally invasive treatments are increasingly favored by both doctors and patients because they involve quicker recovery times, fewer risks, and shorter hospital stays. The American Heart Association and American Stroke Association recommend neuroendovascular coiling for the initial treatment of most intracranial aneurysm types, making it an important alternative to surgical clipping.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $1 Billion |
Forecast Value | $1.9 Billion |
CAGR | 6% |
The bare platinum coils segment in the neuroendovascular coil market held 52.8% share in 2024. These coils are widely used due to their proven clinical effectiveness in treating intracranial aneurysms. Once placed, bare platinum coils provide reliable aneurysm occlusion over time, even as they age. The long-standing clinical track record of these coils ensures minimal complication rates, making them the preferred choice for many cases. Their established reliability continues to drive demand in both developed and emerging markets. Additionally, the price point of bare platinum coils offers an advantage in healthcare systems where cost sensitivity is a significant factor, and reimbursement is not always available.
Hospitals represented the dominant segment in the neuroendovascular coil market, contributing a 69.1% share in 2024. Hospitals worldwide are increasingly setting up dedicated units for stroke and neurovascular care to meet the growing demand for time-sensitive procedures such as aneurysm coiling. These specialized units rely heavily on a steady supply of neuroendovascular coils, which are essential for treating cerebrovascular diseases. With the focus on neurological care and preventing complications after stroke, the demand for advanced coiling devices has risen significantly. In high-income nations, private insurance providers and public healthcare systems offer supportive reimbursement policies for hospital-based endovascular therapies.
U.S Neuroendovascular Coil Market is expected to reach 752.2 million by 2034. The country's extensive network of specialized stroke centers and neurosurgical departments facilitates a high volume of neuroendovascular procedures. This robust healthcare infrastructure promotes the widespread use of neuroendovascular coils and supports the adoption of new technologies over time. The steady growth of these healthcare facilities and the increasing uptake of neuroendovascular treatment technologies are key factors contributing to the market's expansion in the U.S.
Key players in the Global Neuroendovascular Coil Market include: Acandis, Allium Medical, Balt, Boston Scientific, Cardinal Health, Cook Medical, Kaneka, Medtronic, MicroPort, MicroVention, Penumbra, Rapid Medical, Shape Memory Medical, Stryker, Terumo. To solidify their position in the neuroendovascular coil market, companies are focusing on multiple strategies. These include heavy investments in research and development to introduce advanced coil technologies, with a particular focus on improving safety, precision, and delivery mechanisms. By developing new coil materials and designs, manufacturers are responding to the growing demand for more effective treatments for complex aneurysms. Companies are also expanding their geographic reach through partnerships and collaborations with hospitals and medical centers, particularly in regions where healthcare infrastructure is rapidly developing.